Albuminuria in Rheumatoid Arthritis: Associations With Rheumatoid Arthritis Characteristics and Subclinical

Amanda Sammut1, Steven Shea1, Roger S Blumenthal2

  • 1Columbia University College of Physicians & Surgeons, New York, New York.

Insights

Albuminuria, a marker for cardiovascular disease (CVD), is not associated with subclinical CVD in rheumatoid arthritis (RA) patients. Tumor necrosis factor inhibitors may reduce elevated urine albumin-to-creatinine ratio (uACR) in RA.

Area of Science:

  • Rheumatology
  • Cardiology
  • Nephrology

Background:

  • Albuminuria is a recognized indicator of subclinical cardiovascular disease (CVD) in the general population.
  • Rheumatoid arthritis (RA) patients exhibit increased atherosclerosis and CVD events, but the role of albuminuria in this population is unclear.

Purpose of the Study:

  • To investigate the association between elevated urine albumin-to-creatinine ratio (uACR) and subclinical CVD in patients with RA compared to non-RA controls.
  • To explore the relationship between uACR, CVD risk factors, and atherosclerosis measures in RA patients.

Main Methods:

  • Cross-sectional comparison of 196 RA patients and 271 non-RA controls.
  • Measurement of urine albumin-to-creatinine ratio (uACR) from spot morning collections.
  • Assessment of associations with CVD risk factors and atherosclerosis measures (coronary artery calcification, carotid intima-media thickness, carotid plaque).

Main Results:

  • Elevated uACR prevalence was similar between RA patients (18%) and controls (17%).
  • RA was associated with 57% lower odds of elevated uACR after adjustment (P=0.016).
  • Elevated uACR was not associated with atherosclerosis or cardiometabolic risk factors in RA patients. Treatment with tumor necrosis factor inhibitors was associated with lower uACR prevalence (9% vs. 20%, P=0.047).

Conclusions:

  • Elevated uACR is not a reliable indicator of subclinical CVD in RA patients.
  • The association between uACR and CVD risk factors differs between RA patients and controls.
  • Tumor necrosis factor inhibitor use may be linked to a reduced prevalence of elevated uACR in RA.
Abstract

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
697
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
833
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.2K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
835
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
667
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
789